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Insulin regimens and glycemic control in different parts of Europe over 4 years after starting insulin in people with type 2 diabetes: Data from the CREDIT non-interventional study 1 .
Introduction
Insulin therapy is generally started when people with type 2 diabetes on oral therapies can no longer attain the recommended targets for blood glucose control. Various types of insulin have been recommended [1] [2] [3] , with some authorities sanctioning basal or premix, while others emphasize basal insulin only. Mealtime insulin alone is occasionally recommended when starting insulin as is a mealtime + basal insulin regimen [4] . Evidence on the relative efficacy of insulin regimens has been provided in randomized clinical trials [5, 6] , but these trials may not be representative of the people and clinical environments found in routine clinical practice. Some of the challenges of generalizability intrinsic to randomized trials may be overcome in non-interventional observational studies, and they may be a bridge toward more routine clinical settings [4] .
The Cardiovascular Risk Evaluation in People With Type 2 Diabetes on Insulin Therapy (CREDIT) study, an international, 4-year, non-interventional, longitudinal study, was designed to evaluate, in routine clinical practice, the relationship between blood glucose control and cardiovascular events in people beginning any insulin and to provide insight into current medical practice in people with type 2 diabetes using insulin [7] . The study was conducted in Canada, Japan and 10 countries in Europe from December 2006 to May 2012. Baseline data and 1-and 4-year blood glucose-related results have been reported in detail for the overall population [7] [8] [9] [10] .
The aim of the current study was to dissect out some of the differences in clinical practice when starting insulin in different parts of Europe, specifically in terms of the population starting insulin, insulin regimens used, and concomitant therapies, and resultant outcome. We hoped to gain a better understand of the diversity of clinical behavior and perhaps shed light on the reasons for some of the differences. To maintain reasonable pools of data, we report blood glucose-related outcomes at 4 years in study-defined regions of eastern (E), northern (N) and southern (S) Europe, concentrating on characteristics when starting insulin, choice of insulin regimen, evolution of insulin therapy and metabolic outcomes.
Materials and methods
The CREDIT study design, site/participant selection process and participant baseline characteristics have been reported previously [7] . Ethical approval was obtained for all study sites. Study conduct adhered to data collection standards for clinical trials, according to the Declaration of Helsinki. All participants gave written informed consent prior to enrollment. Men and women aged >40 years with type 2 diabetes were eligible if they had started any insulin regimen >1 month and <12 months prior to study entry and had an HbA1c measurement within 3 months before beginning insulin. Data when starting insulin were collected retrospectively from clinical records and included micro-/macrovascular disease and high blood pressure as well as starting insulin regimen. Microvascular disease was defined as having nephropathy, retinopathy and/or peripheral neuropathy. Macrovascular disease was defined as having myocardial infarction, stable angina, severe unstable angina leading to hospitalization, heart failure, stroke, transient ischemic attack, peripheral vascular disease, myocardial revascularization, peripheral revascularization and/or lower limb amputation. High blood pressure was defined as !130/!80 mmHg.
Starting insulin regimens were classified as basal, basal + mealtime, mealtime, premix and other, where other was a mix of these. There was no fixed study visit schedule, and insulin choice, dosage, titration and concomitant oral agent therapy were according to usual local practice. Data were gathered from routine clinical practice from people starting any insulin in E Europe (Croatia, Russia, Ukraine), N Europe (Finland, Germany, United Kingdom) and S Europe (France, Italy, Portugal, Spain).
Physicians were asked to report updated data every 6 months. Data at 1, 2, 3 and 4 years represent those ascertained 9-18, 18-30, 30-42, and 42-54 months after starting insulin, respectively. Glucose control was assessed by HbA1c, fasting plasma glucose (FPG) and postprandial plasma glucose (PPPG). HbA1c is presented in both National Glycohemoglobin Standardization Program and International Federation of Clinical Chemistry units, locally measured [11, 12] . FPG and PPPG are reported as either laboratory-or self-monitored glucose values. PPPG values were obtained approximately 2 h post-meal. Documented symptomatic hypoglycemia, nocturnal hypoglycemia and severe hypoglycemia were assessed retrospectively over the 6 months prior to the follow-up visit date. Symptomatic hypoglycemia was an event with clinical symptoms confirmed by blood glucose 3.9 mmol/l. Nocturnal hypoglycemia was hypoglycemia that occurred while the patient was asleep, after bed-time and before getting up in the morning. Severe hypoglycemia was an event that required assistance of another person and either confirmed blood glucose <2.0 mmol/l or prompt recovery after oral carbohydrate, intravenous glucose or glucagon administration. Changes of insulin regimen, other glucose-lowering medications and body weight change were assessed.
Statistical methods
Analyses were performed with SAS software, version 9.2 (Cary, NC, USA). All data are reported and analyzed using descriptive statistics. All data (when starting insulin and yearly data) are presented for each regional population. The percentage and 95% CIs of participants on individual insulin regimens are presented for each regional population. Comparative statistical testing was not performed because of the likelihood of some degree of allocation bias, avoiding the danger of spurious statistically significant findings with the high numbers of people studied.
Results
A total of 2236 (74.6%) of the 2999 eligible participants were from Europe: 735 from E Europe, 460 from N Europe and 1041 from S Europe (Supplemental Table 1 ). Of those 2236 participants, 1699 (76.0%) had 4-year data. There were differences in baseline characteristics between regions (Table 1 ). More participants from E Europe were female, younger and had shorter diabetes duration, yet had higher HbA1c and had more micro-/macrovascular disease when beginning insulin than those from the other regions. In each region, the baseline characteristics of participants without 4-year data were similar to those of all participants in that region (Supplemental Table 2 ). Across the regions, 73%-100% of the 228 physicians were specialists (diabetologist/endocrinologist/internist) in an urban location (68-100%). The percentage of physicians with their practice office-based, hospital-based or both was 25.0%, 43.8% and 31.3% in E Europe; 40.0%, 52.5% and 7.5% in N Europe; and 48.9%, 16.8% and 34.3% in S Europe. Most physicians were males in N Europe (65.0%) and S Europe (55.1%), whereas 91.8% were female in E Europe.
Insulin regimens
Approximately 60%-64% of participants in all three regions initiated insulin with only a basal formulation, and use of this at 4 years had declined in all to 30%-38% of participants, with the biggest fall in N Europe (Fig. 1) . A basal + mealtime regimen had the greatest use at baseline in E Europe (15%) and had a slightly lower use in S Europe. However, there was a marked increase in use of this regimen in all regions by 4 years, again most notably in E Europe (40% at 4 years), with the least increase in N Europe. Premix insulin had the greatest baseline use in N Europe (28%), expanding by 4 years to 34%, but with no change in E Europe (22% at both times) and little change (13%-16%) in S Europe. Accordingly, participants in all regions appear to be moving primarily to a basal bolus regimen with time. Few participants in any region started on mealtime (2%-5%) or ''other" insulin regimens (0.4%-6%), with proportions remaining below 10% at 4 years. However, while More of these participants across regions (48%-61%) remained on basal insulin than any other regimen; in N Europe, 39% also remained on premix. At 4 years, more participants in E Europe were prescribed basal insulin alone (42% vs 26%), basal + mealtime insulin (43% vs 32%) and pre-mix insulin (62% vs 20%) by hospitalbased rather than office-based physicians. In N Europe, more participants were prescribed basal insulin alone (61% vs 20%) and basal + mealtime insulin (64% vs 33%) by office-based physicians, whereas more were prescribed pre-mix insulin by hospital-based physicians (63% vs 33%). In S Europe, more participants were prescribed basal insulin alone (49% vs 22%) and pre-mix insulin (36% vs 24%) by office-based physicians, whereas more were prescribed basal + mealtime insulin (68% vs 21%) and other insulin (55% vs 27%) by hospitalbased physicians. The percentage of participants prescribed an insulin regimen by physicians with both an office-and hospital-based practice ranged from 17%-32% in E Europe; 2.5%-11% in N Europe; and 18%-40% in S Europe, with the highest percentage observed with basal insulin alone in E Europe and N Europe and with pre-mix insulin in S Europe. Overall, similar results were observed when starting insulin.
Other glucose-lowering medications
Of the eligible participants starting insulin, 71%-78% were taking !1 other glucose-lowering medication across regions ( Table 1 ). The proportion of participants taking only one other glucose-lowering medication when starting insulin ranged from 30% in S Europe to 44% in E Europe, while a similar proportion across regions were taking two other medications (30%-35%). Those taking !3 other glucose-lowering medications ranged from 1% in E Europe to 9% in S Europe. Metformin use was lower (43%) and sulfonylurea use greater (57%) in E Europe than in the other regions; use of glucoselowering medications other than metformin or sulfonylurea was limited in all regions. Across regions at 4 years, 62%-67% were taking !1 other glucose-lowering medication ( Table 2 ). Similar proportions of participants were taking one (37%-44%) or two (15%-22%) other glucose-lowering medication across regions, while those taking !3 other medications ranged from 0.4% in E Europe to 8% in S Europe. Metformin use across regions at 4 years was similar to that when starting insulin, whereas sulfonylurea use across regions declined to 15%-29%. Use of glucose-lowering medications other than metformin or sulfonylurea, while still low, did increase in all regions. This increase was predominantly due to use of dipeptidylpeptidase-4 (DPP-4) inhibitors in E Europe and to DPP-4 inhibitors and glucagon-like peptide-1 receptor (GLP-1R) agonists in N and S Europe.
Insulin dose
The Table 2 ). Most of the decline in HbA1c, FPG and PPPG occurred in the first year (Fig. 2 ).
Hypoglycemia
Reported hypoglycemia by any measure tended to be highest in E Europe and lowest in N Europe. Thus, the percentage of participants who reported at least one hypoglycemia episode in the last 6 months of each year ranged from a high of 22.6% at year 2 to a low of 20.7% at year 4 in E Europe, from 12.3% at year 1 to 8.3% at year 4 in N Europe and from 16.6% at year 1 to 14.2% at year 4 in S Europe (Fig. 2) of participants in E Europe who reported at least one severe hypoglycemia episode was 3.6%, 4.1%, 5.2% and 4.7% in the last 6 months of years 1-4. In N Europe, these proportions appear lower at 0.5%, 0.8%, 1.4% and 0.9%, as also in S Europe at 1.0%, 0.8%, 0.5% and 0.9%. In S Europe the incidence of documented symptomatic hypoglycemia tended to be higher in participants taking insulin alone, compared with the groups using oral agents (including/not including a sulfonylurea) in addition to insulin (Supplemental Table 3 ). Within the other regions incidence was similar between the three groups. The event rates, and incidence of severe hypoglycemia, had too high variance to allow valid judgement between regions.
Body weight change
Body weight differed at starting insulin between the three regions ( Table 2) ; most of the gain occurred in the first year (Fig. 2 ).
Discussion
The CREDIT study assessed the relationship between blood glucose control and cardiovascular events in people with type 2 diabetes beginning any insulin regimen in real-world medical practice. Overall results have been published elsewhere [7] . From this study, we report the evolution of different insulin regimens and blood glucose control change over 4 years in E, N and S Europe, concentrating on the differences between regions and identifying clinically relevant differences. Indeed, it seems that the populations with type 2 diabetes starting insulin in the three defined regions differed, with the E European group starting in poorer glucose control but achieving a greater reduction in HbA1c even in the first year. The figures for this group are not dissimilar from the overall data in the A1chieve study, performed in non-Western countries [4] . In that study, the authors attributed the large improvements in glucose control as much to changes in patient education and behavior as to the insulins themselves, largely because in that study body weight did not increase and hypoglycemia was minimal, independent of the insulin used. By contrast, HbA1c in N Europe was lower when insulin was started (though still poor) and decreased the smallest amount despite reasonable insulin dosage, perhaps suggesting the gain in control here was to a greater extent due to the insulin rather than improved patient education and motivation. Although there were marked differences in type of physician involved in starting insulin between the regions (Table 1) , these reflect some known factors such as the high number of diabetologist specialists in Italy, the long-standing predominance of women as specialists in ex-Soviet countries and differences in structure of care in individual countries in Europe, with no regional pattern [13, 14] . Therefore it does not seem possible to attribute differences in baseline characteristics or care provided when starting insulin to physician characteristics.
In the current study, weight gain was similar in the three regions, albeit in the context of the less improvement in glucose control in N Europe. Baseline body weight appeared to differ, but is broadly consistent with WHO population data suggesting obesity is a particular problem in two of our northern European countries, intermediate in eastern Europe and less of a problem in Italy [15] , perhaps reflecting known cultural differences in eating. Reported hypoglycemia was also lower in this region. Possible explanations are differences in attitudes to recording hypoglycemic symptoms, or because expectations of people with diabetes and/or their clinicians over hypoglycemia and weight gain differed.
In all regions, basal insulin was most commonly used to initiate insulin therapy. However, patterns of insulin use did differ over time. A prandial + basal regimen was already more common in E Europe when starting insulin, perhaps reflecting the poorer initial glucose control, and became dominant with time. This was not true of N Europe, where premix use, already high as a starting regimen, was used by one-third of participants by 4 years, compared with around a quarter still on basal and a quarter on a basal bolus regimen. Premix use could be related to patient preferences for a lower number of injections.
Stopping insulin, presumably switching to oral therapies in those in whom glucose control had improved, was rare in E Europe but occurred in a significant percentage of people in N Europe. Whether this relates to differences in physician practice, such as a higher preference for non-insulin therapies or better adherence to lifestyle changes, is unclear. In the overall population, people stopping insulin had the best final glucose control [7] . An alternative explanation, in a non-interventional study like CREDIT, is the presence of unknown differences in the patient populations in different regions; for example, people starting insulin at the time of an acute metabolic crisis or hospital admission for another reason might be more likely to be able to stop it again subsequently.
The difference in metformin and sulfonylurea use is not unexpected; sulfonylureas were always the mainstay of oral agent therapy in Europe until after the UKPDS study reports [16, 17] , and the metformin evidence base seems to have had a lower/slower impact in E Europe than in W Europe, where IDF and EASD guidelines have had significant impact. However, even in the 4 years of study, some evolution is seen in that regard, though the impact of weight gain and hypoglycemia may also have been significant in driving the change in balance of oral agents.
The study has a number of limitations. Compared with the other regions, a greater percentage of participants from E Europe were women, though this does not seem to impact duration of diabetes, body mass index and macrovascular complications in ways that might be expected. This bias may be related to evidence from other studies suggesting that men in this region may have less awareness of health issues, be more reluctant to visit doctors and have a lower level of self-care health [8] , but might also be related to recruitment bias related to time off from employment or willingness to share data. It is not, however, possible to know whether a more typical proportion of men, as in the other regions, would have brought the E European data more into line with those from S and N Europe, or resulted in a greater deviation. It is also possible that cultural and medical care considerations affected reporting of rates of hypoglycemia, which are known to vary widely between studies. However, our definitions depend on confirmation by self-monitoring, so if anything, one might expect the greater access in W Europe to give higher rates, the opposite of what was found.
Irrespective of the regimen, the mean starting dose of insulin was generally lower in N Europe, but the dose at 4 years was generally higher than in other regions. Again, this suggests greater initial therapeutic caution in these countries, with the poorer glucose control driving dose titration in time. Examination of data pertaining to age, duration of diabetes, body mass index or concomitant medication use does not suggest these as explanations.
This sub-analysis is encouraging in confirming the overall study results, that patients in all regions had a marked and sustained (4-year) reduction in HbA1c after beginning insulin and that the rates of hypoglycemia including severe hypoglycemia and nocturnal hypoglycemia were relatively modest and did not increase with time.
In conclusion, in different parts of Europe, insulin in the CREDIT study was initiated at different levels of glucose control, with some notable differences in evolution of insulin regimens and of reported hypoglycemia. The findings may relate to differences in medical practice and resources. Nevertheless, the findings are generally positive in all regions, perhaps more so where the baseline situation was poorer, and the improvements were generally sustained, independent of the insulin regimen used.
